Literature DB >> 17564428

Analysis of signaling pathways in 90 cancer cell lines by protein lysate array.

Kanchana Natarajan Mendes1, Daniel Nicorici, David Cogdell, Ioan Tabus, Olli Yli-Harja, Rudy Guerra, Stanley R Hamilton, Wei Zhang.   

Abstract

UNLABELLED: Multiple signal transduction pathways play a crucial role in cancer development, progression, and response to different therapies. An important issue is whether common signal transduction pathways are ubiquitously altered in all cancer types and some unique pathways are involved in different cancer types. Another important issue is whether and how transduction signaling molecules are heterogeneously expressed and activated in different cancer cells within and between cancer cell types.
METHODS: To gain insight into these issues, we assembled a protein lysate array with 90 different cell lines of 12 different cell types. Each sample is diluted 2-fold six times, and samples from the dilution series were printed three times on the array. We then measured the expression levels and phosphorylation status of 52 different signaling proteins with specific antibodies and carried out statistical hierarchical clustering analysis.
RESULTS: The most significant finding based on the cluster analysis was that the cell lines did not group based on tumor types, suggesting that the signaling pathways studied were commonly activated in most of the tumor types cultured in vitro. As expected, related proteins associated with specific signaling pathways clustered together, and analysis of the 30 most differentially expressed proteins revealed the PI3-K signaling pathway was upregulated in several different tumor types and the VEGF-angiogenesis pathway was downregulated in hematopoetic cancers. Another important observation, with clinical implications was that EGFR was the most heterogeneous among all the cell lines. We also observed signaling pathways unique to specific types of cancers such as the inverse relationship between p16ink and Rb, and the EGFR mediated pathway activation characteristic of pancreatic cancers.
CONCLUSIONS: Using reverse phase lysate array analysis in this study, we were able to determine potential relationships and signaling pathways, both common and unique, to different types of cancer using cell lines in vitro. This data could be utilized for mining information related to an individual cancer of interest and combined with morphological and genomic profiles would help in creating a combination of expression markers and/or functional signaling maps for specific cancer diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17564428     DOI: 10.1021/pr070184h

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  13 in total

1.  Reno: regularized non-parametric analysis of protein lysate array data.

Authors:  Bin Li; Feng Liang; Jianhua Hu; And Xuming He
Journal:  Bioinformatics       Date:  2012-03-30       Impact factor: 6.937

2.  Microarray methods for protein biomarker detection.

Authors:  Hye Jin Lee; Alastair W Wark; Robert M Corn
Journal:  Analyst       Date:  2008-06-05       Impact factor: 4.616

3.  Variable slope normalization of reverse phase protein arrays.

Authors:  E Shannon Neeley; Steven M Kornblau; Kevin R Coombes; Keith A Baggerly
Journal:  Bioinformatics       Date:  2009-03-31       Impact factor: 6.937

4.  Robust microarray production of freshly expressed proteins in a human milieu.

Authors:  Fernanda Festa; Sean M Rollins; Krishna Vattem; Margarita Hathaway; Phillip Lorenz; Eliseo A Mendoza; Xiaobo Yu; Ji Qiu; Greg Kilmer; Penny Jensen; Brian Webb; Ed T Ryan; Joshua LaBaer
Journal:  Proteomics Clin Appl       Date:  2013-05-17       Impact factor: 3.494

5.  Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug.

Authors:  Jilong Yang; James A Eddy; Yuan Pan; Andrea Hategan; Ioan Tabus; Yingmei Wang; David Cogdell; Nathan D Price; Raphael E Pollock; Alexander J F Lazar; Kelly K Hunt; Jonathan C Trent; Wei Zhang
Journal:  Mol Cell Proteomics       Date:  2010-07-22       Impact factor: 5.911

Review 6.  Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens.

Authors:  Allison Marrero; Scott Lawrence; Deborah Wilsker; Andrea Regier Voth; Robert J Kinders
Journal:  Semin Oncol       Date:  2016-06-14       Impact factor: 4.929

7.  IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.

Authors:  Lynette M Moore; Kristen M Holmes; Sarah M Smith; Ying Wu; Elena Tchougounova; Lene Uhrbom; Raymond Sawaya; Janet M Bruner; Gregory N Fuller; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-16       Impact factor: 11.205

8.  Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots.

Authors:  E Shannon Neeley; Keith A Baggerly; Steven M Kornblau
Journal:  Cancer Inform       Date:  2012-04-11

9.  RNAi-based validation of antibodies for reverse phase protein arrays.

Authors:  Heiko A Mannsperger; Stefan Uhlmann; Christian Schmidt; Stefan Wiemann; Ozgür Sahin; Ulrike Korf
Journal:  Proteome Sci       Date:  2010-12-23       Impact factor: 2.480

10.  Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker.

Authors:  Adriana Aguilar-Mahecha; Christiane Cantin; Maureen O'Connor-McCourt; Andre Nantel; Mark Basik
Journal:  Proteome Sci       Date:  2009-04-06       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.